Nasotasone (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, modulating gene expression. This action increases anti‑inflammatory proteins and suppresses pro‑inflammatory cytokines, leading to reduced swelling, mucus production and irritation within the nasal passages.

The prescribed dose of Nasotasone is determined by the treating clinician based on the patient’s age, severity of symptoms and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers typically weigh the potential benefits against any possible risks before prescribing it to pregnant or nursing individuals.

To request Nasotasone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasotasone (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents such as fluticasone, it may achieve symptom control at similar or lower dosing frequencies, but choice of therapy depends on individual patient response and prescriber preference.

Nasotasone should be stored at room temperature, below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed when not in use.

Nasotasone is delivered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal mucosa. Patients should report any unusual symptoms to their healthcare provider promptly.

Nasotasone should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, active nasal infections, recent nasal surgery or trauma, and in patients for whom systemic corticosteroid exposure is contraindicated.